Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patricia Galvan

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.
Science Translational Medicine|April 17, 2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerAna Bosch, Zhiqiang Li, Anna Bergamaschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
European Journal of Nuclear Medicine and Molecular Imaging|April 8, 2024
Clinicopathological and molecular predictors of [<sup>18</sup>F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trialAntonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, et al.
Science Translational Medicine|April 17, 2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerAna Bosch, Zhiqiang Li, Anna Bergamaschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2023
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast CancerJamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, et al.
Pageof 2